Diabetes Engagement and Activation Platform

Completed · Not applicable

Conditions studied: Type 2 Diabetes (T2D)

In brief

The following are hypothesized: 1. The Diabetes Engagement and Activation Platform (DEAP) can be integrated into primary care workflow to facilitate the care of patients with type 2 diabetes. 2. The DEAP intervention will be feasible and acceptable to patients with type 2 diabetes. 3. The DEAP intervention will enhance patient activation and improve type 2 diabetes self management and glucose control

Key facts

Study ID

NCT02957721

Run by

Virginia Commonwealth University

People needed

350

Starts

2017-11-01

Expected to finish

2018-11-05

Last updated by the study team

2018-11-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with type 2 diabetes and A1C measure ≥ 8%;
• English speaking;
• Enrolled in the practice EHR linked patient portal.

You may not qualify if…

• Patients without type 2 diabetes or with type 2 diabetes who have a A1C less than or equal to 7.9%;
• Non-English speaking;
• Patients not enrolled in the practice EHR linked patient portal;
• Under 18 and over 75 years of age.

Where it is running

• Virginia Commonwealth University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.